Personalized cancer test could match patients to best drugs

NCT ID NCT07171554

Recruiting now Diagnosis Sponsor: Oncosyne AS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new diagnostic test called µCAN that takes a small sample of a patient's tumor and grows it in the lab. The test then screens many drugs to see which ones kill the cancer cells best. The goal is to help doctors choose the right treatment for each person with metastatic colorectal cancer. The study will enroll 75 patients in Norway and Sweden to see if the test can produce a useful report within 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: µCAN drug screen test (diagnostic test using patient-derived tumoroids)
What this could lead to: If successful, this test could help doctors choose the most effective drugs for each patient with metastatic colorectal cancer, potentially improving treatment outcomes and reducing side effects.
What could go wrong: This is an early-stage study with only 75 participants, focused on whether the test can produce a usable report, not yet on whether it improves survival. The test may not work for all patients or may not lead to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (MCRC)

Contacts and locations

Locations

Akershus University Hospital
RECRUITING

Lørenskog, Akershus, 1478, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.